- Afatinib - clinical practice experience2018 | Second Faculty of Medicine
- The effect of afatinib on lung cancer in clinical practice2015 | Faculty of Medicine in Hradec Králové
- Tolerancy of treatment with afatinib on our group of patients2014 | Faculty of Medicine in Pilsen
- Afatinib - non-small cell lung cancer in the second generation targeted therapy2014 | Publication without faculty affiliation
- Afatinib as first-line therapy of advanced lung cancer2014 | First Faculty of Medicine
- Management of diarrhea as an undesirable effect of treatment with afatinib - case report2017 | Faculty of Medicine in Pilsen
- Afatinib - drug profile2017 | Publication without faculty affiliation
- Targeted treatment of NSCLC with kinase inhibitors - afatinib and nintedanib in clinical pracitce2017 | Faculty of Medicine in Pilsen
- Current position of afatinib in the therapy of non-small cell lung carcinoma2017 | Publication without faculty affiliation
- Starší pacientka léčená afatinibem2016 | First Faculty of Medicine
- LUX-LUNG 7 - new look at the first line treatment for patients with frequent EGFR mutations?2016 | Faculty of Medicine in Pilsen
- Research Report University Hospital of the clinical trial 1200.55Publication without faculty affiliation
- Lung adenocarcinoma with a rare EGFR mutation and infrequent resistance to treatment2022 | Faculty of Medicine in Pilsen, Central Library of Charles University
- Postavení afatinibu v léčbě nemalobuněčného plicního karcinomu2018 | First Faculty of Medicine
- Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study2021 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Central Library of Charles University
- Patient with three EGFR mutations - gradual development of resistance to previous targeted treatment2018 | Faculty of Medicine in Pilsen, Faculty of Science
- Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial2019 | First Faculty of Medicine
- Komentář ke studii (Afatinib vs. erlotinib ve 2. linii léčby pacientů s pokročilým skvamózním karcinomem plic - studie LUX-Lung 8)2016 | First Faculty of Medicine
- Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial2019 | Publication without faculty affiliation
- Current treatment options for squamous cell carcinoma of the lung2018 | Faculty of Medicine in Pilsen
- Management of advanced non-small cell lung cancer +12015 | First Faculty of Medicine
- New alternatives and approaches in the treatment of advanced non-small cell lung cancer2015 | Faculty of Medicine in Pilsen
- Real-life effectiveness of first-line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry2020 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Central Library of Charles University
- Komentář k metaanalýze studií nintedanib + docetaxel2018 | Second Faculty of Medicine
